Foghorn Therapeutics (FHTX)

• Market cap: $314M
• 1 day: -5.58%
• 5 days: 3.96%
• 1 month: -15.19%
• 3 months: 29.63%
• 6 months: 2.94%
• Year to date: 14.38%
• 1 year: -37.50%
• 5 years: -71.03%
• 10 years: -71.03%
• Sector: Healthcare
• Industry: Biotechnology

About: Foghorn Therapeutics Inc is engaged in the discovery and development of a new class of medicines targeting genetically determined dependencies within the chromatin regulatory system. Its proprietary Gene Traffic Control platform gives an integrated, mechanistic understanding of how the various components of the chromatin regulatory system interact, allowing it to identify, validate, and potentially drug targets within the system. The company is developing FHD-286, a selective, allosteric ATPase inhibitor, and FHD-609, a protein degrader, to treat hematologic cancers and solid tumors.

Employees: 112

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

133% more repeat investments, than reductions

Existing positions increased: 35 | Existing positions reduced: 15

30% more capital invested

Capital invested by funds: $148M [Q1] → $192M (+$44.8M) [Q2]

0.72% more ownership

Funds ownership: 72.68% [Q1] → 73.4% (+0.72%) [Q2]

0% more funds holding in top 10

Funds holding in top 10: 2 [Q1] → 2 (+0) [Q2]

0% more call options, than puts

Call options by funds: $1K | Put options by funds: $1K

12% less funds holding

Funds holding: 89 [Q1] → 78 (-11) [Q2]

53% less first-time investments, than exits

New positions opened: 8 | Existing positions closed: 17